Effect of matrix metalloproteinase inhibition on pancreatic cancer invasion and metastasis: An additive strategy for cancer control

Annals of Surgery

Volumn 231, Issue 5, 2000, Pages 644-654

  Jimenez, Ramon E ^a   Hartwig, Werner ^a   Antoniu, Bozena A ^a   Compton, Carolyn C ^a   Warshaw, Andrew L ^a   Fernández Del Castillo, Carlos ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASEMENT MEMBRANE; CANCER CONTROL; CANCER MORTALITY; CELL INVASION; DRUG EFFECT; DRUG POTENCY; ENZYME INHIBITION; METASTASIS; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; METALLOENDOPEPTIDASES; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PHENYLALANINE; THIOPHENES; TUMOR CELLS, CULTURED;

EID: 0034060279     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-200005000-00004     Document Type: Article

References (37)

1. Bramhall SR. The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application. Int J Pancreatol 1997; 21:1-12.
2. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997; 91:439-442.
3. Docherty AJ, Murphy G. The tissue metalloproteinase family and the inhibitor TIMP: a study using cDNAs and recombinant proteins. Ann Rheum Dis 1990; 49:469-479.
4. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991; 51:5054s-5059s.
5. Martinez-Hernandez A. Amenta PS. The basement membrane in pathology. Lab Invest 1983; 48:656-677.
6. Charpin C, Lissitzky JC, Jacquemier J, et al. Immunohistochemical detection of laminin in 98 human breast carcinomas: a light and electron microscopic study. Hum Pathol 1986; 17:355-365.
7. Forster SJ, Talbot IC, Clayton DG, Critchley DR. Tumour basement membrane laminin in adenocarcinoma of rectum: an immunohistochemical study of biological and clinical significance. Int J Cancer 1986; 37:813-817.
8. Basset P, Bellocq JP, Wolf C. et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990; 348:699-704.
9. Muller D, Breathnach R, Engelmann A, et al. Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumours. Int J Cancer 1991; 48:550-556.
10. Ponton A, Coulombe B, Skup D. Decreased expression of tissue inhibitor of metalloproteinases in metastatic tumor cells leading to increased levels of collagenase activity. Cancer Res 1991; 51:2138-2143.
11. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992; 326:455-465.
12. Gress TM, Muller-Pillasch F, Lerch MM, Friess H, Buchler M, Adler G. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995; 62:407-413.
13. Koshiba T, Hosotani R, Wada M, et al. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer 1998; 82:642-650.
14. Bramhall SR, Neoptolemos JP, Stamp GW, Lemoine NR. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 1997; 182:347-355.
15. Bramhall SR, Stamp GW, Dunn J, Lemoine NR, Neoptolemos JP. Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. Br J Cancer 1996; 73:972-978.
16. von Marschall Z, Riecken EO, Rosewicz S. Stromelysin 3 is overexpressed in human pancreatic carcinoma and regulated by retinoic acid in pancreatic carcinoma cell lines. Gut 1998; 43:692-698.
17. Zervos EE, Shafii AE, Haq M, Rosemurgy AS. Matrix metalloproteinase inhibition suppresses MMP-2 activity and activation of PANC-1 cells in vitro. J Surg Res 1999; 84:162-167.
18. Zervos EE, Shafii AE, Rosemurgy AS. Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer. J Surg Res 1999; 81:65-68.
19. Eccles SA, Box GM, Court WJ, Bone EA, Thomas W, Brown PD. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 1996; 56:2815-2822.
20. Watson SA, Morris TM, Parsons SL, Steele RJ, Brown PD. Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model. Br J Cancer 1996; 74:1354-1358.
21. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1993; 53:2087-2091.
22. Zervos EE, Norman JG, Gower WR, Franz MG, Rosemurgy AS. Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo. J Surg Res 1997; 69:367-371.
23. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980; 102:196-202.
24. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370:61-65.
25. Panis Y, Nordlinger B. Animal models for colorectal liver metastases. In: Jeppsson B, ed. Animal Modelling in Surgical Research. Amsterdam: Harwood Academic Publishers; 1998:203-210.
26. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 1994; 54:4726-4728.
27. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999; 189:1-7.
28. Connolly MM, Dawson PJ, Michelassi F, Moossa AR, Lowenstein F. Survival in 1001 patients with carcinoma of the pancreas. Ann Surg 1987; 206:366-373.
29. Singh SM, Longmire WPJ, Reber HA. Surgical palliation for pancreatic cancer. The UCLA experience. Ann Surg 1990; 212:132-139.
30. Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 1999; 85:1261-1268.
31. Poen JC, Ford JM, Niederhuber JE. Chemoradiotherapy in the management of localized tumors of the pancreas. Ann Surg Oncol 1999; 6:117-122.
32. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 1998; 17:279-284.
33. Chirivi RG, Garofalo A, Crimmin MJ, et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 1994; 58:460-464.
34. Watson SA, Morris TM, Robinson G, Crimmin MJ, Brown PD, Hardcastle JD. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 1995; 55:3629-3633.
35. DeVita VT. Principles of cancer management: chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott-Raven; 1999:333-348.
36. Todd KE, Gloor B, Lane JS, Isacoff WH, Reber HA. Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole. J Gastrointest Surg 1998; 2:159-166.
37. Jones L, Ghaneh P, Humphreys M, Neoptolemos JP. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Ann NY Acad Sci 1999; 880:288-307.